The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss
Open accessAbstract
Mutations in PINK1 and PARK2 cause autosomal recessive parkinsonism, a neurodegenerative disorder that is characterized by the loss of dopaminergic neurons. To discover potential therapeutic pathways, we identified factors that genetically interact with Drosophila park and Pink1. We found that overexpression of the translation inhibitor Thor (4E-BP) can suppress all of the pathologic phenotypes, including degeneration of dopaminergic neurons in Drosophila. 4E-BP is activated in vivo by the TOR inhibitor rapamycin, which could potently suppress pathology in Pink1 and park mutants. Rapamycin also ameliorated mitochondrial defects in cells from individuals with PARK2 mutations. Recently, 4E-BP was shown to be inhibited by the most common cause of parkinsonism, dominant mutations in LRRK2. We also found that loss of the Drosophila LRRK2 homolog activated 4E-BP and was also able to suppress Pink1 and park pathology. Thus, in conjunction with recent findings, our results suggest that pharmacologic stimulation of 4E-BP activity may represent a viable therapeutic approach for multiple forms of parkinsonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This aberrant protein synthesis is, in part, mediated by dysregulation of LRRK2 phosphorylation of ribosomal proteins (5,6) and PTEN-induced kinase 1 (PINK1) and parkin modulation of eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP) (7).”
From Enhanced mTORC1 signaling and Protein Synthesis in Parkinson’s Disease Pathogenesis Disease Pathogenesis (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defects in mRNA translation are linked to autosomal dominant PD (5,6) and autosomal recessive PD (7), where there is aberrant bulk protein synthesis that is coupled to neurodegeneration (8,9).”
From Enhanced mTORC1 signaling and Protein Synthesis in Parkinson’s Disease Pathogenesis Disease Pathogenesis (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, activation of 4E-BP1 by rapamycin treatment is sufficient to rescue dopamine neuron loss and motor deficits in Drosophila PINK1 and parkin models of DA neuron loss (7).”
From Enhanced mTORC1 signaling and Protein Synthesis in Parkinson’s Disease Pathogenesis Disease Pathogenesis (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
FOXO1 Regulates the Expression of 4E-BP1 and Inhibits mTOR Signaling in Mammalian Skeletal Muscle
Southgate, R. J., Neill, B., Prelovsek, O., El‐Osta, A., Kamei, Y., Miura, S., Ezaki, O., McLoughlin, T. J., Zhang, W., Unterman, T. G., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702039200 · Cited by 112
RetractedTOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Levine, B., & Klionsky, D. J. (2004) · Developmental Cell · doi:10.1016/s1534-5807(04)00099-1 · Cited by 3,728
Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans
Murphy, C. T., McCarroll, S. A., Bargmann, C. I., Fraser, A., Kamath, R. S., Ahringer, J., Li, H., & Kenyon, C. (2003) · Nature · doi:10.1038/nature01789 · Cited by 2,280
eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,103
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
Translational control in stress and apoptosis
Holčı́k, M., & Sonenberg, N. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1618 · Cited by 1,409
Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway
Kapahi, P., Zid, B. M., Harper, T., Koslover, D., Sapin, V., & Benzer, S. (2004) · Current Biology · doi:10.1016/j.cub.2004.03.059 · Cited by 1,293
Flagged first, then by citations
Cited by
Sorted by citations
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
mTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676
The lysosome as a cellular centre for signalling, metabolism and quality control
Lawrence, R. E., & Zoncu, R. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0244-7 · Cited by 920
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., & Kroemer, G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.22 · Cited by 842
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
Human iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777
FOXO/4E-BP Signaling in Drosophila Muscles Regulates Organism-wide Proteostasis during Aging
Demontis, F., & Perrimon, N. (2010) · Cell · doi:10.1016/j.cell.2010.10.007 · Cited by 656
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 652
Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains
Alvarez‐Erviti, L., Rodríguez-Oroz, M. C., Cooper, J. A. D., Caballero, C., Ferrer, I., Obeso, J. A., & Schapira, A. H. V. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.198 · Cited by 577
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Cookson, M. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2935 · Cited by 552
Fighting neurodegeneration with rapamycin: mechanistic insights
Bové, J., Martínez‐Vicente, M., & Vila, M. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn3068 · Cited by 533
Posttranscriptional Upregulation by MicroRNAs
Vasudevan, S. (2011) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.121 · Cited by 536
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003985 · Cited by 508
Schapira, A. H. V. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61305-6 · Cited by 514
The Role of Autophagy in Parkinson's DiseasePreprint
Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M., & Klionsky, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009357 · Cited by 477
Recent Advances in the Genetics of Parkinson's Disease
Martin, I., Dawson, V. L., & Dawson, T. M. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101440 · Cited by 451
Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression
Gehrke, S., Imai, Y., Sokol, N. S., & Lu, B. (2010) · Nature · doi:10.1038/nature09191 · Cited by 398
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bézard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 399
Molecular neurobiology of mTOR
Switon, K., Kotulska, K., Janusz, A., Zmorzyńska, J., & Jaworski, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.017 · Cited by 405
Protein homeostasis and aging in neurodegeneration
Douglas, P. M., & Dillin, A. G. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.201005144 · Cited by 381
Crews, L. A., Spencer, B. J., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E. M., Hansen, L. A., Adame, A., Galasko, D. R., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 379
RetractedmTOR in Brain Physiology and Pathologies
Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 381
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D. S., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 340
Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2
Mortiboys, H., Johansen, K. K., Aasly, J. O., & Bandmann, O. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ff9685 · Cited by 320
Self-citationEmerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam‐Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 316
Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease
Chartier‐Harlin, M., Dächsel, J. C., Vilariño‐Güell, C., Lincoln, S., Leprêtre, F., Hulihan, M., Kachergus, J. M., Milnerwood, A. J., Tapia, L., Song, M.-S., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.08.009 · Cited by 316
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Moors, T. E., Hoozemans, J. J. M., Ingrassia, A. M. T., Beccari, T., Parnetti, L., Chartier‐Harlin, M., & van de Berg, W. D. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0154-3 · Cited by 287
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D. S., & Foltynie, T. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 280
Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson’s Disease
Martin, I., Kim, J. W., Lee, B. D., Kang, H. C., Xu, J.-C., Jia, H., Stankowski, J., Kim, M.-S., Zhong, J., Kumar, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.064 · Cited by 265
Drosophila melanogaster in the Study of Human Neurodegeneration
Hirth, F. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791556104 · Cited by 247
Gao, F., Dong, C., Si, J., Hu, Q., Qin, Z., Fang, M., & Wang, G. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv017 · Cited by 239
mTOR: on target for novel therapeutic strategies in the nervous system
Maiese, K., Chong, Z. Z., Shang, Y., & Wang, S. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.11.001 · Cited by 226
Mitophagy and Parkinson's disease: The PINK1–parkin link
Deas, E., Wood, N. W., & Plun‐Favreau, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.08.007 · Cited by 230
Haynes, C. M., Fiorese, C. J., & Lin, Y. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.02.002 · Cited by 213
Stressin’ Sestrins take an aging fight
Budanov, A. V., Lee, J. H., & Karin, M. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000097 · Cited by 208
Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses
Won, H., Mah, W., & Kim, E. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00019 · Cited by 217
Regulation of mRNA Translation in Neurons—A Matter of Life and Death
Kapur, M., Monaghan, C. E., & Ackerman, S. L. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.057 · Cited by 208
Molecular and clinical prodrome of Parkinson disease: implications for treatment
Schapira, A. H. V., & TOLOSA, E. S. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.52 · Cited by 210
Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders
Maiese, K. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12804 · Cited by 202
Translational control in cellular and developmental processes
Kong, J., & Lasko, P. F. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3184 · Cited by 193
Vallelunga, A., Ragusa, M., Mauro, S. D., Iannitti, T., Pilleri, M., Biundo, R., Weis, L., Pietro, C. D., Iuliis, A. D., Nicoletti, A. S. Q., et al. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00156 · Cited by 180
Meng, H., Yamashita, C., Shiba‐Fukushima, K., Inoshita, T., Funayama, M., Sato, S., Hatta, T., Natsume, T., Umitsu, M., Takagi, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15500 · Cited by 171
LRRK2 pathobiology in Parkinson's disease
Martin, I., Kim, J. W., Dawson, V. L., & Dawson, T. M. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12949 · Cited by 176
Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162
Parkinson's disease: insights from pathways
Cookson, M., & Bandmann, O. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq167 · Cited by 166
Self-citationAutophagy Dysregulation in Amyotrophic Lateral Sclerosis
Chen, S., Zhang, X., Song, L., & Le, W. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00546.x · Cited by 170
MicroRNAs in Parkinson's disease
Harraz, M. M., Dawson, T. M., & Dawson, V. L. (2011) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2011.01.005 · Cited by 161
mTOR/AMPK signaling in the brain: Cell metabolism, proteostasis and survival
Garza-Lombó, C., Schroder, A. L., Reyes‐Reyes, E. M., & Franco, R. (2018) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2018.05.002 · Cited by 169
Parkinson's disease and cancer: two wars, one front
Devine, M. J., Plun‐Favreau, H., & Wood, N. W. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3150 · Cited by 155
Elstner, M., Morris, C. M., Heim, K., Bender, A., Mehta, D., Jaros, E., Klopstock, T., Meitinger, T., Turnbull, D. M., & Prokisch, H. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0828-9 · Cited by 150
Fernandes, H. J. R., Patikas, N., Foskolou, S., Field, S. F., Park, J.-E., Byrne, M. L., Bassett, A. R., & Metzakopian, E. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108263 · Cited by 141
Therapeutic prospects for Parkinson disease
Olanow, C. W., & Schapira, A. H. V. (2013) · Annals of Neurology · doi:10.1002/ana.24011 · Cited by 145
Loreto, A., Hill, C. S., Hewitt, V. L., Orsomando, G., Angeletti, C., Gilley, J., Lucci, C., Sanchez-Martinez, A., Whitworth, A. J., Conforti, L., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104678 · Cited by 131
Self-citationXu, J., Wu, P., Jiang, W., Liu, Y., Jiang, J., Kuang, S., Tang, L., Tang, W., Zhang, Y., Zhou, X., et al. (2016) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2016.05.021 · Cited by 141
Primary Skin Fibroblasts as a Model of Parkinson's Disease
Auburger, G. W. J., Klinkenberg, M., Drost, J., Marcus, K., Morales-Gordo, B., Kunz, W. S., Brandt, U., Broccoli, V., Reichmann, H., Gispert, S., et al. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8245-1 · Cited by 146
Role of TOR signaling in aging and related biological processes in Drosophila melanogaster
Katewa, S. D., & Kapahi, P. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.11.036 · Cited by 139
Zheng, X., Boyer, L. F., Jin, M., Kim, Y., Fan, W., Bardy, C., Berggren, W. T., Evans, R. M., Gage, F. H., & Hunter, T. R. (2016) · eLife · doi:10.7554/elife.13378 · Cited by 139
Protein translation: biological processes and therapeutic strategies for human diseases
Jia, X., He, X., Huang, C., Li, J., Dong, Z., & Liu, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01749-9 · Cited by 164
Liu, Z., Hamamichi, S., Lee, B. D., Yang, D., Ray, A., Caldwell, G. A., Caldwell, K. A., Dawson, T. M., Smith, W. W., & Dawson, V. L. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr312 · Cited by 139
LRRK2 and mitochondria: Recent advances and current views
Singh, A., Zhi, L., & Zhang, H. (2018) · Brain Research · doi:10.1016/j.brainres.2018.06.010 · Cited by 137
Defective Autophagy in Parkinson’s Disease: Role of Oxidative Stress
Janda, E., Isidoro, C., Carresi, C., & Mollace, V. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8318-1 · Cited by 134
Repairing the parkinsonian brain with neurotrophic factors
Aron, L., & Klein, R. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.11.001 · Cited by 127
Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson’s disease
Mortiboys, H., Aasly, J. O., & Bandmann, O. (2013) · Brain · doi:10.1093/brain/awt224 · Cited by 124
Self-citationA Critical Kinase Cascade In Neurological Disorders: Pi3K, Akt and Mtor
Chong, Z. Z., Shang, Y., Wang, S., & Maiese, K. (2012) · Future Neurology · doi:10.2217/fnl.12.72 · Cited by 122
Garelick, M. G., & Kennedy, B. K. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.08.030 · Cited by 120
Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models
Domanskyi, A., Geißler, C., Vinnikov, I. A., Alter, H., Schober, A., Vogt, M. A., Gass, P., Parlato, R., & Schütz, G. (2011) · The FASEB Journal · doi:10.1096/fj.11-181958 · Cited by 121
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin
Chong, Z. Z., Shang, Y. C., Wang, S., & Maiese, K. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.001 · Cited by 119
Lee, S., Liu, H., Lin, W., Guo, H.-F., & Lu, B. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1807-10.2010 · Cited by 117
Etiology and Pathogenesis of Parkinson Disease
Schapira, A. H. V. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2009.04.004 · Cited by 120
mTOR Signaling in Parkinson’s Disease
Lan, A., Chen, J., Zhao, Y., Chai, Z., & Hu, Y. (2016) · NeuroMolecular Medicine · doi:10.1007/s12017-016-8417-7 · Cited by 117
An overview of rapamycin: from discovery to future perspectives
Yoo, Y. J., Kim, H., Park, S. R., & Yoon, Y. J. (2016) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-016-1834-7 · Cited by 114
The Relevance of Insulin Action in the Dopaminergic System
Fiory, F., Perruolo, G., Cimmino, I., Cabaro, S., Pignalosa, F. C., Miele, C., Bèguinot, F., Formisano, P., & Oriente, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00868 · Cited by 118
Jiang, W., Hu, K., Zhang, J.-X., Liu, Y., Jiang, J., Wu, P., Zhao, J., Kuang, S., Tang, L. Y., Tang, W., et al. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515003219 · Cited by 110
Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation
Martínez‐Vicente, M. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.03.005 · Cited by 114
Role of Autophagy in Parkinson’s Disease
Cerri, S., & Blandini, F. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180226094351 · Cited by 107
Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
Maiese, K., Chong, Z. Z., Wang, S., & Shang, Y. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131113830 · Cited by 109
Drosophila as a Model to Study Mitochondrial Dysfunction in Parkinson's DiseasePreprint
Guo, M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009944 · Cited by 111
Andexer, J. N., Kendrew, S. G., Nur‐e‐Alam, M., Lazos, O., Foster, T. A., Zimmermann, A.-S., Warneck, T. D., Suthar, D., Coates, N. J., Koehn, F. E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015773108 · Cited by 104
Liu, S., & Lu, B. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001237 · Cited by 105
Unravelling mitochondrial pathways to P arkinson's disease
Celardo, I., Martins, L. M., & Gandhi, S. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12433 · Cited by 105
Drosophila Models of Parkinson's Disease
Whitworth, A. J. (2011) · Advances in genetics · doi:10.1016/b978-0-12-380860-8.00001-x · Cited by 110
Self-citationFields, J. A., Serger, E., Campos, S., Divakaruni, A. S., Kim, C., Smith, K., Trejo, M., Adame, A., Spencer, B. J., Rockenstein, E. M., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.11.015 · Cited by 102
MKK6 binds and regulates expression of Parkinson’s disease‐related protein LRRK2
Hsu, C. H., Chan, D., Greggio, E., Saha, S., Guillily, M. D., Ferree, A. W., Raghavan, K., Shen, G. C., Segal, L., Ryu, H., et al. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06568.x · Cited by 100
Muñoz, V. F. L., & Paricio, N. (2011) · Parkinson s Disease · doi:10.4061/2011/520640 · Cited by 104
Key genes and convergent pathogenic mechanisms in Parkinson disease
Coukos, R., & Krainc, D. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00812-2 · Cited by 116
Chen, L., Song, J., Lu, J., Yuan, Z., Liu, L., Durairajan, S. S. K., & Li, M. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9528-2 · Cited by 97
Hexokinase activity is required for recruitment of parkin to depolarized mitochondria
McCoy, M. K., Kaganovich, A., Rudenko, I. N., Ding, J., & Cookson, M. R. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt407 · Cited by 97
TOR and ageing: a complex pathway for a complex process
McCormick, M. A., Tsai, S., & Kennedy, B. K. (2010) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2010.0198 · Cited by 99
Mechanisms of Parkinson's Disease
Hewitt, V. L., & Whitworth, A. J. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.07.005 · Cited by 97
Self-citationTherapeutic implication of autophagy in neurodegenerative diseases
Rahman, M. A., & Rhim, H. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.7.069 · Cited by 100
Kumar, A., Greggio, E., Beilina, A. G., Kaganovich, A., Chan, D., Taymans, J., Wolozin, B. L., & Cookson, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008730 · Cited by 94
Modeling Parkinson’s Disease in Drosophila: What Have We Learned for Dominant Traits?
Xiong, Y., & Yu, J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00228 · Cited by 99
Lowered Insulin Signalling Ameliorates Age-Related Sleep Fragmentation in Drosophila
Metaxakis, A., Tain, L. S., Grönke, S., Hendrich, O., Hinze, Y., Birras, U., & Partridge, L. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001824 · Cited by 94
Self-citationKanao, T., Venderová, K., Park, D. S., Unterman, T. G., Lu, B., & Imai, Y. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq289 · Cited by 91
Wang, Y., Liu, Y., Zhang, X.-Y., Xu, L., Ouyang, D., Liu, K., Pan, H., He, J., & He, X. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.07.028 · Cited by 92
Choi, I., Kim, J., Jeong, H., Kim, B., Jou, I., Park, S. M., Chen, L.-N., Kang, U. J., Zhuang, X., & Joe, E.-H. (2013) · Glia · doi:10.1002/glia.22475 · Cited by 90
Yuan, Y., Cao, P., Smith, M. A., Kramp, K., Huang, Y., Hisamoto, N., Matsumoto, K., Hatzoglou, M., Jin, H., & Feng, Z. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022354 · Cited by 93
Hou, Y.-S., Guan, J.-J., Xu, H.-D., Wu, F., Sheng, R., & Qin, Z.-H. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00285-15 · Cited by 87
Biosynthesis of rapamycin and its regulation: past achievements and recent progress
Park, S. R., Yoo, Y. J., Ban, Y. H., & Yoon, Y. J. (2010) · The Journal of Antibiotics · doi:10.1038/ja.2010.71 · Cited by 90
LRRK2 signaling pathways: the key to unlocking neurodegeneration?
Berwick, D. C., & Harvey, K. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.01.001 · Cited by 86
Metadata
- Authors
- Tain, L. S., Mortiboys, H., Tao, R. N., Ziviani, E., Bandmann, O., & Whitworth, A. J.
- Affiliations
- Medical Research Council (GB)
- Corresponding author
- Whitworth, Alexander J
- Venue
- Nature Neuroscience
- Published
- 2009-08-16
- Volume
- 12
- Issue
- 9
- Pages
- 1129-1135
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- PMC
- PMC2745154
- OpenAlex
- W1991190713
- Cited by
- 323
- References
- 50
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 11 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 18 · 2019: 17 · 2018: 14 · 2017: 17 · 2016: 26 · 2015: 21 · 2014: 24 · 2013: 18 · 2012: 27
- FWCI
- 24.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Wellcome Trust (081987, GR077544AIA)
- Parkinson's UK (G-0713, G-1007, G-4063, G-0715)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- 4E-BP, rapamycin, Parkinson's disease, Parkin, PINK1, dopaminergic neuron loss, protein synthesis inhibition, TOR signaling, LRRK2, mitochondrial defects, genetic interactions, Drosophila, neurodegeneration, therapeutic target
- MeSH terms
- PTEN-Induced Putative Kinase, Animals, Cell Survival, Dopamine, Drosophila, Fibroblasts, Glutathione Transferase, Humans, Locomotion, Mitochondria, Muscles, Nerve Degeneration, Neurons, Peptide Initiation Factors, Protein Serine-Threonine Kinases, Neuroprotective Agents, Sirolimus, Drosophila Proteins, Animals, Genetically Modified, Ubiquitin-Protein Ligases, Intracellular Signaling Peptides and Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
